MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 529525 | Name: Elvucitabine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Elvucitabine is a reverse transcriptase inhibitor potentially for the treatment of HBV infection and HIV infection.

Chemical Structure

Elvucitabine
Elvucitabine
CAS#181785-84-2

Theoretical Analysis

MedKoo Cat#: 529525

Name: Elvucitabine

CAS#: 181785-84-2

Chemical Formula: C9H10FN3O3

Exact Mass: 227.0706

Molecular Weight: 227.19

Elemental Analysis: C, 47.58; H, 4.44; F, 8.36; N, 18.50; O, 21.13

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
181785-84-2
Synonym
ACH-126443; ACH126443; ACH 126443; L-D-4FC; beta-L-Fd-4C; TY-202; LD-4FC; betaLFd-4C; LD4FC; TY202; LD4FC; betaLFd4C
IUPAC/Chemical Name
4-amino-5-fluoro-1-((2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1H)-one
InChi Key
HSBKFSPNDWWPSL-VDTYLAMSSA-N
InChi Code
InChI=1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m1/s1
SMILES Code
O=C1N=C(N)C(F)=CN1[C@H]2O[C@@H](CO)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 227.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Colucci P, Pottage JC, Robison H, Turgeon J, Ducharme MP. Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers. Antimicrob Agents Chemother. 2009 Feb;53(2):646-50. doi: 10.1128/AAC.00905-08. PubMed PMID: 19015353; PubMed Central PMCID: PMC2630647. 2: Colucci P, Pottage JC, Robison H, Turgeon J, Schürmann D, Hoepelman IM, Ducharme MP. Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects. Antimicrob Agents Chemother. 2009 Feb;53(2):662-9. doi: 10.1128/AAC.00907-08. PubMed PMID: 19015343; PubMed Central PMCID: PMC2630663. 3: Elvucitabine data released at CROI. AIDS Patient Care STDS. 2010 Mar;24(3):198. PubMed PMID: 20235383. 4: Hernandez-Santiago BI, Mathew JS, Rapp KL, Grier JP, Schinazi RF. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. Antimicrob Agents Chemother. 2007 Jun;51(6):2130-5. PubMed PMID: 17403996; PubMed Central PMCID: PMC1891415. 5: Otto MJ. New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections. Curr Opin Pharmacol. 2004 Oct;4(5):431-6. Review. PubMed PMID: 15351346. 6: Meusinger R. Doubling spectroscopy challenge. Anal Bioanal Chem. 2015 Nov;407(27):8169-72. doi: 10.1007/s00216-015-9002-x. PubMed PMID: 26463052. 7: Desai M, Iyer G, Dikshit RK. Antiretroviral drugs: critical issues and recent advances. Indian J Pharmacol. 2012 May;44(3):288-98. doi: 10.4103/0253-7613.96296. PubMed PMID: 22701234; PubMed Central PMCID: PMC3371447. 8: Ghosh RK, Ghosh SM, Chawla S. Recent advances in antiretroviral drugs. Expert Opin Pharmacother. 2011 Jan;12(1):31-46. doi: 10.1517/14656566.2010.509345. Review. PubMed PMID: 20698725. 9: Stellbrink HJ. Novel compounds for the treatment of HIV type-1 infection. Antivir Chem Chemother. 2009;19(5):189-200. Review. PubMed PMID: 19483267. 10: Schinazi RF, Massud I, Rapp KL, Cristiano M, Detorio MA, Stanton RA, Bennett MA, Kierlin-Duncan M, Lennerstrand J, Nettles JH. Selection and characterization of HIV-1 with a novel S68 deletion in reverse transcriptase. Antimicrob Agents Chemother. 2011 May;55(5):2054-60. doi: 10.1128/AAC.01700-10. PubMed PMID: 21357304; PubMed Central PMCID: PMC3088218. 11: dD4FC development discontinued. AIDS Clin Care. 2006 May;18(5):47. PubMed PMID: 16718907. 12: Hammond JL, Parikh UM, Koontz DL, Schlueter-Wirtz S, Chu CK, Bazmi HZ, Schinazi RF, Mellors JW. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine. Antimicrob Agents Chemother. 2005 Sep;49(9):3930-2. PubMed PMID: 16127074; PubMed Central PMCID: PMC1195387. 13: Feinberg J. Meeting notes from the 3rd IAS Conference. New drugs. AIDS Clin Care. 2005 Oct;17(10):96-7. PubMed PMID: 16276591. 14: Susman E. HIV Pathogenesis and Treatment - Third International AIDS Society Conference. IDrugs. 2005 Oct;8(10):813-5. PubMed PMID: 16254799. 15: Waters L, Nelson MR. New drugs. HIV Med. 2005 Jul;6(4):225-31. Review. PubMed PMID: 16011526. 16: Sax PE. Meeting notes from ICAAC. D-D4FC (Reverset): further data on treatment-experienced patients. AIDS Clin Care. 2005 Jan;17(1):8. PubMed PMID: 15717377. 17: Stuyver LJ, McBrayer TR, Schürmann D, Kravec I, Beard A, Cartee L, Schinazi RF, De La Rosa A, Murphy RL, Otto MJ. Potent antiviral effect of reverset in HIV-1-infected adults following a single oral dose. Antivir Ther. 2004 Aug;9(4):529-36. PubMed PMID: 15456084. 18: De Clercq E. Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005 May;10(2):241-73. Review. PubMed PMID: 15934866. 19: Murakami E, Ray AS, Schinazi RF, Anderson KS. Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of D- and L-D4FC-TP. Antiviral Res. 2004 Apr;62(1):57-64. PubMed PMID: 15026203. 20: Sagir A, Avci A, Erhardt A, Lörke J, Heintges T, Häussinger D. [New approaches in the treatment of hepatitis B]. Dtsch Med Wochenschr. 2004 May 21;129(21):1203-8. Review. German. PubMed PMID: 15160325.